Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAVA-051 in Relapsed or Refractory CLL, MM, or AML
NCT04887259Phase 1Terminated
- Sponsor
- LAVA Therapeutics
- Start
- Jul 2021
- Primary completion
- Sep 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of LAVA-051 in chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML) (2 arms), sponsored by LAVA Therapeutics. Primary endpoints: Frequency and severity of Adverse Events at 6 months and Frequency and type of Dose Limiting Toxicities at 28 days. Started Jul 2021; status: terminated.
02
Drugs
LAVA-051
03
Conditions
chronic lymphocytic leukemia (CLL)multiple myeloma (MM)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04887259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04887259.